-
Je něco špatně v tomto záznamu ?
Azaindoles: Suitable ligands of cytotoxic transition metal complexes
P. Štarha, Z. Trávníček,
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, práce podpořená grantem
- MeSH
- cytotoxiny * chemická syntéza chemie terapeutické užití MeSH
- indoly * chemická syntéza chemie terapeutické užití MeSH
- komplexní sloučeniny * chemická syntéza chemie terapeutické užití MeSH
- lidé MeSH
- nádory farmakoterapie metabolismus patologie MeSH
- přechodné kovy chemie MeSH
- protinádorové látky * chemická syntéza chemie terapeutické užití MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
This minireview is devoted to the complexes of various transition metals, which contain azaindole ring coordinated to the metal centre, and whose cytotoxicity was studied. We decided to overview this interesting group of coordination compounds with the aim to highlight various structural types of complexes depending on the metal centre (i.e., Pt, Pd, Ru, Ir or Au) and type of the used co-ligand(s). The presented complexes are also reviewed in context of their toxicity, selectivity and processes connected with their mechanism of action. Some of complexes were also studied on in vivo models showing promising results comparable with the commonly used anticancer drug cisplatin. It can be deduced from the herein overviewed literature data regarding transition metal complexes containing azaindoles as ligands, that at least a few of them may represent suitable and promising candidates in the field of anticancer therapy. As one of the examples, the cis-[PtI2(2Me4Cl-7aza)2] complex (2Me4Cl-7aza = 2-methyl-4-chloro-7-azaindole) should be mentioned, which showed considerably higher in vitro cytotoxicity than cisplatin, the ability to overcome both the acquired and natural resistance of human cancer cells in comparison with the biological action of cisplatin, different mechanism of action than cisplatin and comparable in vivo anticancer activity with cisplatin.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20025753
- 003
- CZ-PrNML
- 005
- 20201222155408.0
- 007
- ta
- 008
- 201125s2019 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.jinorgbio.2019.110695 $2 doi
- 035 __
- $a (PubMed)31054487
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Štarha, Pavel $u Biologically Active Complexes and Molecular Magnets, Regional Centre of Advanced Technologies and Materials, Faculty of Science, Palacký University in Olomouc, Šlechtitelů 27, 783 71 Olomouc, Czech Republic. Electronic address: pavel.starha@upol.cz.
- 245 10
- $a Azaindoles: Suitable ligands of cytotoxic transition metal complexes / $c P. Štarha, Z. Trávníček,
- 520 9_
- $a This minireview is devoted to the complexes of various transition metals, which contain azaindole ring coordinated to the metal centre, and whose cytotoxicity was studied. We decided to overview this interesting group of coordination compounds with the aim to highlight various structural types of complexes depending on the metal centre (i.e., Pt, Pd, Ru, Ir or Au) and type of the used co-ligand(s). The presented complexes are also reviewed in context of their toxicity, selectivity and processes connected with their mechanism of action. Some of complexes were also studied on in vivo models showing promising results comparable with the commonly used anticancer drug cisplatin. It can be deduced from the herein overviewed literature data regarding transition metal complexes containing azaindoles as ligands, that at least a few of them may represent suitable and promising candidates in the field of anticancer therapy. As one of the examples, the cis-[PtI2(2Me4Cl-7aza)2] complex (2Me4Cl-7aza = 2-methyl-4-chloro-7-azaindole) should be mentioned, which showed considerably higher in vitro cytotoxicity than cisplatin, the ability to overcome both the acquired and natural resistance of human cancer cells in comparison with the biological action of cisplatin, different mechanism of action than cisplatin and comparable in vivo anticancer activity with cisplatin.
- 650 12
- $a protinádorové látky $x chemická syntéza $x chemie $x terapeutické užití $7 D000970
- 650 12
- $a komplexní sloučeniny $x chemická syntéza $x chemie $x terapeutické užití $7 D056831
- 650 12
- $a cytotoxiny $x chemická syntéza $x chemie $x terapeutické užití $7 D003603
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a indoly $x chemická syntéza $x chemie $x terapeutické užití $7 D007211
- 650 _2
- $a nádory $x farmakoterapie $x metabolismus $x patologie $7 D009369
- 650 _2
- $a přechodné kovy $x chemie $7 D028561
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Trávníček, Zdeněk $u Biologically Active Complexes and Molecular Magnets, Regional Centre of Advanced Technologies and Materials, Faculty of Science, Palacký University in Olomouc, Šlechtitelů 27, 783 71 Olomouc, Czech Republic.
- 773 0_
- $w MED00006646 $t Journal of inorganic biochemistry $x 1873-3344 $g Roč. 197, č. - (2019), s. 110695
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/31054487 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20201125 $b ABA008
- 991 __
- $a 20201222155404 $b ABA008
- 999 __
- $a ok $b bmc $g 1599898 $s 1116439
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 197 $c - $d 110695 $e 20190424 $i 1873-3344 $m Journal of inorganic biochemistry $n J Inorg Biochem $x MED00006646
- LZP __
- $a Pubmed-20201125